drugset / Trial / NCT00162006

Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

NCT00162006

Phase 2 Completed 28 enrolled Baxalta now part of Shire
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution is an effective and safe treatment in patients with chronic idiopathic thrombocytopenic purpura.

Timeline

Start
2003-01-13
Primary completion
2003-12-03
Completion
2003-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic